One of the early studies revealed that neither mutation (on 10 prostatic cancer samples) nor allelic loss (on 34 prostatic cancer samples and 12 metastatic lymph nodes) is the cause of KAI1 gene down-regulation (Dong et al., 1995). Here, CD82 is linked to prostate cancer.